Clinical trial
A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease
NCT02601560 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 3, 2015
- Completion date
- November 3, 2016
- Enrollment
- 48 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.